海纳国际集团(HC Wainwright & Co.)最新研报维持对Compass Pathways公司(CMPS)的股票评级，继续给予每股45美元的目标价位。
该投行分析师团队在最新评估中指出，尽管当前市场波动加剧，但这家专注于精神健康疗法的生物技术公司核心研发管线进展符合预期。特别强调其突破性裸盖菇素疗法COMP360在治疗抵抗性抑郁症(TRD)的三期临床试验数据值得期待，该疗法已获得美国FDA突破性疗法认定。
值得关注的是，该目标价较公司当前股价存在显著溢价空间。市场观察人士指出，若COMP360能在今年第四季度获得监管批准，将成为首个获FDA认可的致幻剂类抑郁症疗法，可能重塑价值数百亿美元的抗抑郁药物市场格局。
截至美东时间7月15日15:16 GMT，Compass Pathways股价在最新交易时段呈现技术性回调，成交量较日均水平放大近三成。期权市场数据显示，部分投资者正通过价外看涨期权布局潜在突破行情。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.